Hemab
Jigar Amin is a seasoned professional in the field of medical affairs, currently serving as the Sr. Director of Medical Affairs and Global External Engagement at Hemab Therapeutics since July 2023. Prior to this role, Jigar held the position of Director of Medical Affairs and Global External Engagement at Alnylam Pharmaceuticals from February 2016 to July 2023, and served as a Medical Science Liaison specializing in rare diseases. Jigar’s career also includes experience as a Senior Hemophilia Medical Liaison at Novo Nordisk from September 2011 to February 2016. Jigar earned a Pharm.D. from the University of Houston from 2007 to 2011 and completed studies at Texas A&M University from 2004 to 2007.
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.